Exosomal RNA: A Novel Signature Guide for Prostate Cancer Proton Therapy

项目摘要/摘要 质子疗法(PT)是一种用于治疗前列腺癌患者的放射疗法，可以是一种 手术的替代方案。虽然PT被认为比传统的放射治疗毒性小，但大约 PT仍然不被理解。帮助他们为当地潮水弗吉尼亚州服务，那里拥有世界上最高的潮水之一 世界前列腺癌发病率，特别是在非裔美国人中，汉普顿大学(HU)，历史上的 布莱克大学开设了汉普顿大学质子治疗研究所。帮助建立这项研究 HU的能力，利用他们在质子治疗方面的临床专业知识，蒙特的伊坎医学院 西奈(ISMMS)和胡提出了这个联合项目，旨在开发一种非侵入性生物标记物，用于应对 PT.ISMMS的团队将带来他们在基因组学和外周体谱方面的专业知识，这是一种非侵入性的方式 测量被认为是从肿瘤脱落到这个项目的颗粒，并在这个过程中帮助建立 胡的研究能力。这个项目的研究目标是确定外体rna的变化。 前列腺癌患者PT放疗前后外显体的(ExoRNA)谱。全 这项研究的目的是使用HU团队在HUPTI收集的患者样本。在目标1中，我们将询问是否存在 根治性前列腺癌根治术前后体外征象有相似的变化。在目标2中， 确定响应PT的mRNA图谱是否有特定变化，我们将全局剖析RNA 从PT前后的外切体中分离出。在目标3中，继续建设这个项目，为 未来合作的R01提交，我们将从HUPTI招募更多的患者到这项研究中并获得 PT前、中、后采血标本。在研究结束时，我们的科学成果 将一直在确定外切体的RNA图谱可以观察到什么变化，以响应PT。 这将是重要的初步数据，证明外周小体用于无创监测甲状旁腺激素。 更重要的是，通过ISMMS和HU之间的合作伙伴关系，我们将加强 HU的研究基础设施，使HU能够与ISMMS和ISMMS联合进行进一步的研究 独立构建他们在质子治疗方面的临床专业知识。

Project Summary / Abstract Proton therapy (PT) is a form of radiation therapy used to treat prostate cancer patients that can be an alternative to surgery. While PT is thought to risk less toxicity than conventional radiation therapy, much about PT is still not understood. To help serve their local area of tidewater Virginia, which has one of the highest rates of prostate cancer in the world, especially in African-Americans, Hampton University (HU), a Historically Black University, has opened the Hampton University Proton Therapy Institute. To help build the research capacity at HU, leveraging their clinical expertise in proton therapy, the Icahn School of Medicine at Mount Sinai (ISMMS) and HU propose this joint project aimed at developing a noninvasive biomarker for response to PT. The team at ISMMS will bring their expertise in genomics and exosome profiling, a noninvasive way to measure particles that are thought to shed from the tumor, to this project and in the process help build the research capacity at HU. The research goal of this project is to determine changes in the exosomal RNA (exoRNA) profile of exosomes taken from prostate cancer patients before and after radiotherapy with PT. All aims of the study use patient samples collected at the HUPTI by the HU team. In aim 1, we will ask if an exosomal signature of radical prostatectomy shows similar changes before and after PT. In aim 2, to determine if there are specific changes in the mRNA profile in response to PT, we will globally profile RNA isolated from exosomes before and after PT. In aim 3, to continue to build this project in preparation for a future collaborative R01 submission, we will recruit additional patients from HUPTI to this study and obtain blood specimens before, during, and after PT. At the end of the study time period, our scientific achievement will have been to determine what changes in the RNA profile of exosomes can be observed in response to PT. This will be important preliminary data demonstrating the utility of exosomes for noninvasive monitoring of PT. More importantly, through this collaborative partnership between ISMMS and HU, we will have enhanced the research infrastructure of HU in a way that will allow HU to pursue further research both jointly with ISMMS and independently building on their clinical expertise in proton therapy.